Flibanserin interactions
Full monograph for FlibanserinCheck it against another medicine
Medicines
312 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Apalutamide | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by… | 3 sources — open the full entry |
| Aprepitant | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily…2 documented mechanisms | 5 sources — open the full entry |
| Betrixaban | Major | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the plasma concentrations of betrixaban, which is a substrate of the… | 11 sources — open the full entry |
| Carbamazepine | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by… | 3 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Chloramphenicol (Oral) | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily…2 documented mechanisms | 14 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Colchicine | Major | Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced… | 78 sources — open the full entry |
| Crizotinib | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily…2 documented mechanisms | 14 sources — open the full entry |
| Digoxin | Major | Excretion | Coadministration with flibanserin may significantly increase the serum concentrations of digoxin. The proposed mechanism is flibanserin inhibition of the… | 4 sources — open the full entry |
| Diltiazem Hydrochloride | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Enzalutamide | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by… | 3 sources — open the full entry |
| ErythromycinLotionOral | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily…2 documented mechanisms | 8 sources — open the full entry |
| Ethanol + Isopropyl alcohol | Major | Synergy | INTERVAL: Coadministration of flibanserin with alcohol may potentiate the risk of severe hypotension, syncope, and central nervous system depression. | 2 sources — open the full entry |
| FluconazolebaseOphthalmic | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Fosphenytoin Sodium | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by… | 3 sources — open the full entry |
| Imatinib Mesylate | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily…2 documented mechanisms | 8 sources — open the full entry |
| Loperamide + Simethicone | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| Loperamide Hydrochloride | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Mifepristone | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Mifepristone + Misoprostol | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Phenobarbital | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by… | 3 sources — open the full entry |
| Phenytoin Sodium | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by… | 3 sources — open the full entry |
| Posaconazole | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Primidone | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by… | 3 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily…2 documented mechanisms | 8 sources — open the full entry |
| Relugolix | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 2 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Absorption · Metabolism | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the…2 documented mechanisms | 36 sources — open the full entry |
| Ribociclib | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Rifampicin | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by… | 3 sources — open the full entry |
| Rifampicin + Isoniazid | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by…2 documented mechanisms | 6 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by…2 documented mechanisms | 6 sources — open the full entry |
| Tucatinib | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Venetoclax | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter. | 5 sources — open the full entry |
| Verapamil Hydrochloride | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily… | 2 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily…2 documented mechanisms | 3 sources — open the full entry |
Food & lifestyle
grapefruit juice
MajorMetabolism
Grapefruit juice may increase the plasma concentrations of flibanserin. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.
What to do: Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors such as grapefruit juice is considered contraindicated. The patient should be advised to avoid the consumption of grapefruit and grapefruit juice during treatment, and to take flibanserin at bedtime to minimize the risk of hypotension, syncope, accidental injury, and central nervous system depression. In addition, patients should consume no more than 1 to 2 alcoholic drinks and discontinue drinking alcohol at least two hours before taking flibanserin at bedtime; otherwise, they should skip the flibanserin dose that evening. Alcohol should not be consumed until at least the morning after taking flibanserin at bedtime. A standard alcoholic drink contains 14 g of pure alcohol and is equivalent to one 12-ounce regular beer (5% alcohol), 5-ounces wine (12% alcohol), or 1.5 ounces of distilled spirits/shot (40% alcohol).
1 source
- "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals (2015):
Conditions
Conditions in which Flibanserin needs care, as documented in this source.
Alcoholic Intoxication
MajorThe use of flibanserin is contraindicated along with the ingestion of alcohol, as it increases the risk of hypotension and syncope. It is important to assess the likelihood of the patient abstaining from alcohol, taking into account the current and past drinking behavior.
1 source
- "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals (2015):
Hypotension
MajorThe use of flibanserin can cause hypotension and syncope. The benefits and risks of therapy should be considered in patients with preexisting conditions that predispose to hypotension. Flibanserin should be used with caution in these patients.
1 source
- "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals (2015):
Liver Diseases
MajorFlibanserin may accumulate in patients with hepatic impairment. Therapy with flibanserin is contraindicated in patients with compromised hepatic function.
1 source
- "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals (2015):